For Our Patients


Clinical Trials and Research

Clinical trials are designed to test the safety and efficacy of new approaches to preventing, detecting, and treating disease. Research and clinical trials also continuously look for new ways to use existing treatments, new drugs, surgical procedures and devices.

Florida Retina Institute clinical trial participants may enroll to possibly receive the newest treatment for their vitreoretinal conditions, as well as to have additional care and attention from clinical trial staff and with the results and outcome of their trial, help researchers find better treatments for future patients.

Detailed information about all Upcoming Studies

For Central Florida Patients

Rezolute, Inc.

A randomized, Double-masked, Placebo-controlled, Parallel-Arm study to Evaluate the Efficacy and safety of RZ402 in participants with Diabetic Macular (DME)


DIAMOND (DX219) - Diabetic Macular Edema

Title: A Phase 2/3 Pivotal, Double-Masked, Randomized, 2-stage, Multicenter Study of Efficacy and Safety of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema


Protocol OCSBFC55-OD1PRK

A phase 2/3 Double-masked, Randomized, 2-stage, Multicenter study of the Efficacy and safety of OCS 01 Eye drops in subjects with Diabetic Macular Edema


Quasar: Retinal Vein Occlusions

Title: Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion. [IND # 12462 (Regeneron Pharmaceuticals, Inc.)]

Enroll in this Study

For North Florida Patients

ADVM-022-11 – LUNA Neovascular (Wet) Age-Related Macular Degeneration

A Multi-Center, Randomized, Double-Masked Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD) [LUNA]


F. Hoffmann-La Roche- Diabetic Macular Edema

A Phase II, Multicenter, Randomized, Double Masked, Active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in patients with Diabetic Macular Edema.


SHANGHAI HENLIUS FOR WET AMD

A Phase 3, Two-part (Open-label Followed by Randomized Double-masked Active Controlled) Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in Subjects with wet Age-related Macular Degeneration (wAMD).


ONL Therapeutics, Inc. (Retinal Detachment)

Protocol: ONL1204-RRD-002
A Phase 2, Randomized, Sham-Controlled, Single-Masked, Dose-Ranging, Multi-Center Study to Assess the Safety and Efficacy of Intravitreal ONL1204 in Subjects with Macula-off Rhegmatogenous Detachment.


Upcoming in 2024 R3918-AMD-2327, DRCR-Protocol AO, KDK-1101-02, Norse Eight


R3918-AMD-2326/2327 Regeneron Pharmaceutics,INC - Dry AMD (GA)

A Randomized, Placebo-Controlled Study of Subcutaneous Pozelimab +
Cemdisiran Combination Therapy or Cemdisiran Monotherapy for the
Treatment of Georgraphic Atrophy, 284291


Protocol No. KDK-1101-02 - CRAO

A Phase 2, Double-masked, Randomized, Sham-controlled,
Multiple-dose Study of the Efficacy and Safety of Intravitreal KUS121
In the Treatment of Non-Arteritic Central Retinal Artery Occlusion (CRAO) – GION-


ONS-5010-008 (NORSE EIGHT) Wet AMD
Safety and Effectiveness of ONS-5010 Compared to Lucentis® in
Subjects with Neovascular Age-related Macular Degeneration;
NORSE EIGHT


Enroll in this Study


If you want to see a list of clinical trials, please click here and go to Clinicaltrials.gov, a resource provided by the U.S. National Library of Medicine. ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.